2023-06-02 11:24:33
Chicago becomes from this Friday until Tuesday the epicenter of cancer research. The American Society of Clinical Oncology (ASCO) celebrates its annual congress again in that city with the focus on less invasive treatments and a better relationship between doctors and patients.
Acronym of the American Society of Clinical Oncology, ASCO, during the Chicago Congress in 2019. EFE/Ana Soteras
According to the organizers of ASCO 2023, this collaboration between professionals and patients stands as the cornerstone of care and research, and will focus part of the agenda of a meeting that expects some 40,000 participants in person, a figure that recovers levels prior to the coronavirus pandemic.
He ASCO president Eric Winer admits that the relationship between doctors and patients has changed in recent years: digital access to medical information -and also misinformation- has been a specific source of confusion, so greater contact between professionals and patients improves both diagnosis and medical expertise itself.
The appointment at the McCormick Place convention center will ask attendees to do an introspection exercise to examine what has gotten better and worse, and what can be done to make interactions more satisfying.
Founded in 1964 by seven oncologists, ASCO’s mission is to end cancer through research, education, and the promotion of fairer, higher-quality healthcare, recognizing that many cancers remain difficult to diagnose. and try.
“We aspire to a world where cancer can be prevented and cured, and where every survivor is healthy. Each cancer, each patient and each medication and treatment are different, ”he explains to EFE the executive vice president of that society and its medical director, Julie Gralowfor whom political will, together with financing, play a determining role.
The latest data from the World Health Organization (WHO) reflect that cancer is one of the leading causes of death worldwide and accounted for some 10 million deaths in 2020, or almost one in six, mainly from cancers. breast, lung, colon and rectum, and prostate.
ASCO 2023: therapeutic novelties
The ASCO 2023 congress serves as a point of exchange for research advances, which point towards less invasive treatments or towards greater precision in the use of drug and antibody conjugates. More than 5,500 abstracts have been submitted.
One of these innovations will come from MEDSIR, a company dedicated to advancing clinical research in oncology based in Spain and the United States.
With the scientific leadership of researchers Javier Cortés, Antonio Llombart-Cussac and José Pérezits phase 2 clinical trial PHERGain, to be presented this Friday afternoon, offers a new individualized approach to treating HER2 positive localized breast cancer and is considered a significant step towards less toxic methods.
The study, according to MEDSIR, evaluates the possibility of “de-escalating” chemotherapy treatments in patients with this subtype of cancer, thanks to an adaptive approach based on the response observed by positron emission tomography (PET) and the pathological response. complete.
He congressthe main one in this specialty, also brings together representatives of institutes such as the French Curie, which will bring to Chicago, among others, the clinical benefits of liquid biopsy, the name by which the blood test is known to confirm or detect the presence of tumor cells.
And it also brings together pharmaceutical companies such as AstraZeneca, which will disseminate results of treatments that it considers could change cancer care. Among them, on the potential of the conjugated antibody trastuzumab deruxtecan in a wide range of HER2 tumors in advanced stages.
According to Gralow, there are reasons for hope. The pace of drug approvals against different cancer classes and targets is so “amazing” that it “is hard to keep up.” “And this is thanks to continued investment,” she concludes.
#Noninvasive #methods #cancer #improve #care